301230 Stock Overview
Operates as a CRO, CDMO, and CMO service provider of drug discovery in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
PharmaResources (Shanghai) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥27.64 |
| 52 Week High | CN¥42.30 |
| 52 Week Low | CN¥16.28 |
| Beta | 1.12 |
| 11 Month Change | 16.62% |
| 3 Month Change | 21.98% |
| 1 Year Change | -8.85% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -1.81% |
Recent News & Updates
Shareholder Returns
| 301230 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | 9.0% | -5.2% | -3.9% |
| 1Y | -8.8% | -30.6% | 4.0% |
Return vs Industry: 301230 exceeded the CN Life Sciences industry which returned -28.1% over the past year.
Return vs Market: 301230 underperformed the CN Market which returned 6.7% over the past year.
Price Volatility
| 301230 volatility | |
|---|---|
| 301230 Average Weekly Movement | 10.5% |
| Life Sciences Industry Average Movement | 10.2% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in CN Market | 12.4% |
| 10% least volatile stocks in CN Market | 5.5% |
Stable Share Price: 301230's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 301230's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 1,012 | Ping Chen | www.pharmaresources.cn |
PharmaResources (Shanghai) Co., Ltd. operates as a CRO, CDMO, and CMO service provider of drug discovery in China. It also manufactures APIs and key intermediates. The company offers preclinical services.
PharmaResources (Shanghai) Co., Ltd. Fundamentals Summary
| 301230 fundamental statistics | |
|---|---|
| Market cap | CN¥3.80b |
| Earnings (TTM) | CN¥6.93m |
| Revenue (TTM) | CN¥513.91m |
548.7x
P/E Ratio7.4x
P/S RatioIs 301230 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301230 income statement (TTM) | |
|---|---|
| Revenue | CN¥513.91m |
| Cost of Revenue | CN¥408.91m |
| Gross Profit | CN¥105.00m |
| Other Expenses | CN¥98.07m |
| Earnings | CN¥6.93m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.05 |
| Gross Margin | 20.43% |
| Net Profit Margin | 1.35% |
| Debt/Equity Ratio | 1.2% |
How did 301230 perform over the long term?
See historical performance and comparison